Literature DB >> 23946218

Severity scoring index for Crimean-Congo hemorrhagic fever and the impact of ribavirin and corticosteroids on fatality.

Basak Dokuzoguz1, Aysel Kocagül Celikbas, Şebnem Eren Gök, Nurcan Baykam, Mustafa Necati Eroglu, Önder Ergönül.   

Abstract

BACKGROUND: Patients infected with Crimean-Congo hemorrhagic fever (CCHF) virus present with a wide clinical spectrum. In observational studies, the effects of therapeutic agents are confounded by severity. We describe use of a clinical severity scoring index (SSI) for CCHF patients and assess the effect of ribavirin and corticosteroid therapy on the case-fatality rate, stratified by SSI.
METHODS: The study group included hospitalized patients who received a diagnosis of CCHF at the Infectious Diseases and Clinical Microbiology Clinic of Ankara Numune Education and Research Hospital between 2004 and 2011. The SSI included platelet count, bleeding, fibrinogen level, activated partial thromboplastin time, and somnolence. The effects of ribavirin and corticosteroid on the case-fatality rate were studied by univariate and multivariate analysis, stratified by SSI.
RESULTS: Two hundred eighty-one confirmed cases of CCHF were included in the study. Of 281 patients, 23 (8%) died. The mean age (±SD) of the patients was 47 ± 16 years. Forty-nine percent were female. The mean duration of stay at our clinic after onset of symptoms was 4.4 days, with a range of 1-14 days. In multivariate analysis of factors for the prediction of death, the SSI (odds ratio [OR], 3.27; 95% confidence interval [CI], 2.09-5.13) and ribavirin use (OR, 0.04; 95% CI, .004-.48) were found to be statistically significant factors.
CONCLUSION: The SSI is an accurate predictor of death and will therefore be a useful tool for case management and for drug-assessment studies. After stratification of cases by SSI, ribavirin was found to be effective in reducing the case-fatality rate, especially among moderately ill patients, whereas steroids were found to be beneficial particularly among patients with severe disease.

Entities:  

Keywords:  Crimean-Congo hemorrhagic fever; corticosteroids; ribavirin; severity scoring index

Mesh:

Substances:

Year:  2013        PMID: 23946218     DOI: 10.1093/cid/cit527

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  24 in total

1.  Identification of 2'-deoxy-2'-fluorocytidine as a potent inhibitor of Crimean-Congo hemorrhagic fever virus replication using a recombinant fluorescent reporter virus.

Authors:  Stephen R Welch; Florine E M Scholte; Mike Flint; Payel Chatterjee; Stuart T Nichol; Éric Bergeron; Christina F Spiropoulou
Journal:  Antiviral Res       Date:  2017-10-09       Impact factor: 5.970

2.  Potential clinical treatment for Ebola pandemic.

Authors:  Ying Zhong; Jun Xu; TaiSheng Li; XueZhong Yu; MiaoMiao Sheng
Journal:  Sci China Life Sci       Date:  2014-09-19       Impact factor: 6.038

3.  Is the brain spared in Crimean-Congo haemorrhagic fever? An MR-SWI study to reveal CNS involvement.

Authors:  Bilge Öztoprak; İbrahim Öztoprak; Aynur Engin
Journal:  Eur Radiol       Date:  2018-03-12       Impact factor: 5.315

4.  Which scoring system is effective in predicting mortality in patients with Crimean Congo hemorrhagic fever? A validation study.

Authors:  Mehmet Bakir; Caner Öksüz; Faruk Karakeçili; Nurcan Baykam; Şener Barut; Seyit Ali Büyüktuna; Zülal Özkurt; Murteza Öz; Orçun Barkay; Özlem Akdoğan; Nazif Elaldi; Murşit Hasbek; Aynur Engin
Journal:  Pathog Glob Health       Date:  2021-12-06       Impact factor: 3.735

5.  Fluorometric CCHFV OTU protease assay with potent inhibitors.

Authors:  Fatih Kocabas; Galip S Aslan
Journal:  Virus Genes       Date:  2015-07-09       Impact factor: 2.332

6.  Validation of a severity grading score (SGS) system for predicting the course of disease and mortality in patients with Crimean-Congo hemorrhagic fever (CCHF).

Authors:  M Bakır; M G Gözel; I Köksal; Z Aşık; Ö Günal; H Yılmaz; A But; G Yılmaz; A Engin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-09-12       Impact factor: 3.267

7.  Direct healthcare costs for patients hospitalized with Crimean-Congo haemorrhagic fever can be predicted by a clinical illness severity scoring system.

Authors:  Ilkay Bozkurt; Mustafa Sunbul; Hava Yilmaz; Saban Esen; Hakan Leblebicioglu; Nicholas J Beeching
Journal:  Pathog Glob Health       Date:  2016-02-25       Impact factor: 2.894

8.  Corticosteroids May Have Negative Effects on the Management of Patients with Severe Fever with Thrombocytopenia Syndrome: A Case-Control Study.

Authors:  Takeshi Kawaguchi; Kunihiko Umekita; Atsushi Yamanaka; Seiichiro Hara; Tetsuro Yamaguchi; Eisuke Inoue; Akihiko Okayama
Journal:  Viruses       Date:  2021-04-28       Impact factor: 5.048

9.  Crimean-Congo hemorrhagic fever among health care workers, Turkey.

Authors:  Aysel Kocagul Celikbas; Başak Dokuzoğuz; Nurcam Baykam; Sebnem Eren Gok; Mustafa Necati Eroğlu; Kenan Midilli; Herve Zeller; Onder Ergonul
Journal:  Emerg Infect Dis       Date:  2014-03       Impact factor: 6.883

10.  Prevalence of Crimean-Congo hemorrhagic fever virus in healthy population, livestock and ticks in Kosovo.

Authors:  Luka Fajs; Isme Humolli; Ana Saksida; Nataša Knap; Mateja Jelovšek; Miša Korva; Isuf Dedushaj; Tatjana Avšič-Županc
Journal:  PLoS One       Date:  2014-11-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.